Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology · Extensive-Stage Small Cell Lung Cancer

Treatment Options for Extensive-Stage SCLC

At a Glance

The standard treatment for extensive-stage small cell lung cancer is chemo-immunotherapy, combining traditional chemotherapy with immune-boosting drugs. If the cancer returns, second-line options like lurbinectedin or new targeted BiTE therapies like tarlatamab can help control the disease.

When small cell lung cancer (SCLC) is diagnosed as extensive-stage (ES-SCLC), it means the cancer has spread beyond one lung or involves distant organs [1]. In this stage, the focus of treatment is on systemic therapy—drugs that travel through the entire bloodstream to attack cancer cells wherever they are located [2].

First-Line Treatment: Chemo-Immunotherapy

For many years, chemotherapy was the only option for ES-SCLC. Today, the standard of care is a powerful combination called chemo-immunotherapy [3][4].

  • Chemotherapy Backbone: This usually involves a “platinum” drug (like carboplatin or cisplatin) paired with etoposide [3].
  • The Immunotherapy Addition: An immune checkpoint inhibitor (ICI) is added to the chemotherapy. The two most common drugs used are atezolizumab and durvalumab [2][5]. These drugs work by “unmasking” cancer cells so your body’s own immune system can recognize and destroy them [6].
  • Maintenance Therapy: It is important to know that you will not be on heavy chemotherapy forever. The harsh chemotherapy portion typically stops after 4 to 6 cycles. If your cancer is stable or shrinking, the immunotherapy continues by itself as a maintenance therapy for as long as it remains effective [2].

Acute Side Effects of Chemotherapy

The initial chemotherapy phase comes with significant side effects. Neutropenic fever (a fever of 100.4°F or higher while your immune system is compromised) is a medical emergency that requires immediate ER evaluation. You should also expect near-universal hair loss, fatigue, and potential nausea during the chemotherapy phase. Always lean on your supportive care team for medications to manage these symptoms.

Second-Line Options: When Cancer Returns

If the cancer stops responding to the first treatment, doctors move to second-line options. The choice often depends on how much time has passed since your last treatment [7].

Lurbinectedin

Lurbinectedin is a common second-line therapy [8]. It works by blocking the cancer cell’s ability to “read” its DNA instructions and by disrupting the supportive environment the tumor creates for itself [9]. It is given as an infusion once every three weeks [10].

Tarlatamab: A New Type of “Bridge” Therapy

Tarlatamab is a recently approved, “first-in-class” drug for patients whose cancer has progressed after chemotherapy [11]. It is a bispecific T-cell engager (BiTE) [12].

Think of a BiTE like a physical bridge with two “hands”:

  1. One hand grabs a protein called DLL3, which is found in high amounts on the surface of SCLC cells [11][13].
  2. The other hand grabs a T-cell (a powerful fighter in your immune system) [11].

By physically pulling the immune cell and the cancer cell together, tarlatamab forces the immune system to attack the tumor [12][14].

Understanding BiTE Side Effects

Because BiTE therapies like tarlatamab activate the immune system so intensely, they can cause unique side effects that require close monitoring [15][16].

  • Cytokine Release Syndrome (CRS): This happens when activated immune cells release a flood of chemicals. It often feels like a severe flu, with high fever, chills, and low blood pressure [15][17].
  • ICANS (Neurotoxicity): This is a type of inflammation that can affect the brain, causing confusion or trouble speaking [18][17].

Most cases of CRS and ICANS are manageable, and doctors often use a “step-up” dosing schedule. You may be asked to stay in or near the hospital for observation during your first dose [16][19].

Return to Understanding Your Small Cell Lung Cancer Diagnosis.

Common questions in this guide

What is the first-line treatment for extensive-stage small cell lung cancer?
The standard first-line treatment is a powerful combination of chemotherapy and immunotherapy. Usually, a platinum chemotherapy drug like carboplatin or cisplatin is paired with etoposide and an immune checkpoint inhibitor.
How long will I need to be on chemotherapy for ES-SCLC?
The harsh chemotherapy portion typically lasts for 4 to 6 cycles. If your cancer is stable or shrinking after these cycles, you will stop chemotherapy and transition to maintenance immunotherapy alone for as long as it remains effective.
What should I do if I get a fever during chemotherapy?
A fever of 100.4°F or higher during chemotherapy is considered a medical emergency called neutropenic fever. Because your immune system is compromised, you should seek immediate evaluation at an emergency room to treat any potential infections safely.
What happens if my lung cancer returns after initial treatment?
If ES-SCLC returns, doctors may recommend second-line therapies based on how much time has passed since your last treatment. Common options include the infusion drug lurbinectedin or newer targeted therapies like tarlatamab.
What is tarlatamab and how does it work?
Tarlatamab is a bispecific T-cell engager (BiTE) therapy used for relapsed small cell lung cancer. It acts like a bridge, grabbing onto a specific protein on the cancer cell and linking it directly to an immune T-cell, forcing your immune system to attack the tumor.
What are the side effects of BiTE therapies like tarlatamab?
Because BiTE therapies strongly activate the immune system, they can cause unique side effects. The most notable are Cytokine Release Syndrome (CRS), which feels like a severe flu, and neurotoxicity (ICANS), which can cause temporary confusion or trouble speaking.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which immunotherapy drug—atezolizumab or durvalumab—is most appropriate for my initial treatment?
  2. 2.How many cycles of the harsh chemotherapy will I receive before switching to maintenance immunotherapy?
  3. 3.What is the exact protocol I should follow if I develop a fever over 100.4°F during my chemotherapy cycles?
  4. 4.If my cancer progresses, would you recommend lurbinectedin or tarlatamab next?
  5. 5.What are the specific protocols for monitoring for CRS and ICANS if I start a BiTE therapy like tarlatamab?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.

    Stinchcombe TE, Fan W, Schild SE, et al.

    Cancer 2019; (125(3)):382-390 doi:10.1002/cncr.31813.

    PMID: 30343497
  2. 2

    First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

    Horn L, Mansfield AS, Szczęsna A, et al.

    The New England journal of medicine 2018; (379(23)):2220-2229 doi:10.1056/NEJMoa1809064.

    PMID: 30280641
  3. 3

    Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting.

    Sands J, Subramanian J

    Frontiers in oncology 2023; (13()):1161931 doi:10.3389/fonc.2023.1161931.

    PMID: 38221913
  4. 4

    Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.

    Melosky B, Cheema PK, Brade A, et al.

    The oncologist 2020; (25(11)):981-992 doi:10.1634/theoncologist.2020-0193.

    PMID: 32860288
  5. 5

    Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

    Paz-Ares L, Dvorkin M, Chen Y, et al.

    Lancet (London, England) 2019; (394(10212)):1929-1939 doi:10.1016/S0140-6736(19)32222-6.

    PMID: 31590988
  6. 6

    Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.

    Zheng J, Deng Y, Huang B, Chen X

    Frontiers in medicine 2023; (10()):1198950 doi:10.3389/fmed.2023.1198950.

    PMID: 37583422
  7. 7

    Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

    Ganti AKP, Loo BW, Bassetti M, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(12)):1441-1464.

    PMID: 34902832
  8. 8

    Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis.

    Tang J, Wang T, Wu H, et al.

    BMC cancer 2024; (24(1)):1351 doi:10.1186/s12885-024-13104-w.

    PMID: 39497053
  9. 9

    Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.

    Rajput PS, Khan SR, Singh P, Chawla PA

    Anti-cancer agents in medicinal chemistry 2022; (22(5)):812-820 doi:10.2174/1871520621666210706150057.

    PMID: 34229593
  10. 10

    Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

    Trigo J, Subbiah V, Besse B, et al.

    The Lancet. Oncology 2020; (21(5)):645-654 doi:10.1016/S1470-2045(20)30068-1.

    PMID: 32224306
  11. 11

    Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies.

    Aijaz A, Pannu S, Abushukair H, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e472794 doi:10.1200/EDBK-25-472794.

    PMID: 40440602
  12. 12

    [New perspectives in the management of small cell bronchial cancer].

    Berton E, Ardin C, Berardi G, et al.

    Bulletin du cancer 2025; (112(3S1)):3S100-3S106 doi:10.1016/S0007-4551(25)00163-8.

    PMID: 40155069
  13. 13

    AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.

    Giffin MJ, Cooke K, Lobenhofer EK, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(5)):1526-1537 doi:10.1158/1078-0432.CCR-20-2845.

    PMID: 33203642
  14. 14

    Tarlatamab for small-cell lung cancer.

    Antoniu S, Penisoara T, Rascu S

    Expert opinion on biological therapy 2025; (25(12)):1275-1283 doi:10.1080/14712598.2025.2606057.

    PMID: 41401368
  15. 15

    Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases.

    Bolte FJ, Dougherty SC, Danos AO, et al.

    Clinical lung cancer 2025; (26(5)):347-353.e1 doi:10.1016/j.cllc.2025.03.006.

    PMID: 40280845
  16. 16

    Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.

    Sands JM, Champiat S, Hummel HD, et al.

    Cancer 2025; (131(3)):e35738 doi:10.1002/cncr.35738.

    PMID: 39876075
  17. 17

    Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database.

    Jin X, Zhao W, Li Y, Peng H

    Naunyn-Schmiedeberg's archives of pharmacology 2026; (399(7)):10097-10110 doi:10.1007/s00210-026-05028-y.

    PMID: 41609856
  18. 18

    Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use.

    Joshi U, Ong F, Melzer D, et al.

    Clinical lung cancer 2026; (27(2)):48-58 doi:10.1016/j.cllc.2025.11.018.

    PMID: 41544604
  19. 19

    Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

    Chiang AC, Olmedo Garcia ME, Carlisle JW, et al.

    ESMO open 2025; (10(4)):104538 doi:10.1016/j.esmoop.2025.104538.

    PMID: 40187110

This page provides educational information about extensive-stage small cell lung cancer treatments and side effects. Always consult your oncology team to determine the safest and most effective therapy for your specific diagnosis.

Get notified when new evidence is published on Small cell lung cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.